MEK inhibitors in oncology: a patent review and update (2016 - present) [0.03%]
肿瘤学中MEK抑制剂的专利回顾与更新（2016-至今）
Anjali Suryavanshi,Vandana,Yugal Kishor Shukla et al.
Anjali Suryavanshi et al.
Introduction: Mitogen-activated protein kinase (MEK) is one of the important components of Ras/Raf/MEK/ERK signaling pathway, transduces signal for cell growth, differentiation, and development. Deregulation of MEK leads ...
Patenting perspective of modulators of ClpP endopeptidase: 2019-present [0.03%]
2019年至今的ClpP内肽酶调节剂专利透视
Zhenyu Wang,Liqing He,Ziheng Fan et al.
Zhenyu Wang et al.
Introduction: ClpP is a highly conserved serine protease that plays a crucial role in maintaining protein homeostasis in both bacterial cells and human mitochondria. Several studies have demonstrated the potential of ClpP...
Helicase-primase inhibitors for the treatment of herpes simplex virus infections - patent evaluation of WO2023/225162 from Gilead Sciences Inc [0.03%]
针对单纯疱疹病毒感染治疗的解螺旋酶-引物酶抑制剂的专利评估：Gilead Sciences Inc公司的WO2023/225162号专利分析
Christian Gege,Gerald Kleymann
Christian Gege
Helicase-primase is an interesting target for small-molecule therapy of herpes simplex virus (HSV) infections. With amenamevir already approved for varicella-zoster virus and herpes simplex in Japan and with pritelivir's granted breakthroug...
Ephrin receptor type-A2 (EphA2) targeting in cancer: a patent review (2018-present) [0.03%]
靶向癌症中 Ephrin 受体A2（EphA2）的专利回顾（2018年至今）
Massimiliano Tognolini,Francesca Romana Ferrari,Alfonso Zappia et al.
Massimiliano Tognolini et al.
Introduction: EphA2 is a tyrosine kinase receptor and is considered a promising target in cancer. Different approaches are used to target EphA2 receptor, and a lot of preclinical data demonstrate the potential exploitatio...
Guotai Feng,Xiao Yang,Wen Shuai et al.
Guotai Feng et al.
Introduction: c-Jun N-terminal kinase (JNK) regulates various biological processes through the phosphorylation cascade and is closely associated with numerous diseases, including inflammation, cardiovascular diseases, and...
Trends in covalent drug discovery: a 2020-23 patent landscape analysis focused on select covalent reacting groups (CRGs) found in FDA-approved drugs [0.03%]
基于FDA批准药物中选定共价反应基团(CRGs)的2020-2023年共价新药发现专利态势分析
Jan Felix Scholtes,Cristobal Alhambra,Philip A Carpino
Jan Felix Scholtes
Introduction: Covalent drugs contain electrophilic groups that can react with nucleophilic amino acids located in the active sites of proteins, particularly enzymes. Recently, there has been considerable interest in using...
Zonghui Ma,Cun Zhang,Andrew A Bolinger et al.
Zonghui Ma et al.
Introduction: Bromodomain-containing protein 4 (BRD4), an important epigenetic reader, is closely associated with the pathogenesis and development of many diseases, including various cancers, inflammation, and infectious ...
Caspase inhibitors: a review on recently patented compounds (2016-2023) [0.03%]
卡肽酶抑制剂：最近的专利化合物回顾(2016-2023)
Shivani Kasana,Shivam Kumar,Preeti Patel et al.
Shivani Kasana et al.
Introduction: Caspases are a family of protease enzymes that play a crucial role in apoptosis. Dysregulation of caspase activity has been implicated in various pathological conditions, making caspases an important focus o...
Tetrahydroisoquinolines - an updated patent review for cancer treatment (2016 - present) [0.03%]
四氢异喹啉类药物治疗癌症的专利更新(2016-至今)
Ankur Kumar Tanwar,Neha Sengar,Nobuyuki Mase et al.
Ankur Kumar Tanwar et al.
Introduction: Cancer is a prominent cause of death globally, triggered by both non-genetic and genetic alterations in genes influenced by various environmental factors. The tetrahydroisoquinoline (THIQ), specifically 1,2,...
A patent review of histone deacetylase 8 (HDAC8) inhibitors (2013-present) [0.03%]
2013年至今组蛋白去乙酰酶8(HDAC8)抑制剂专利回顾
Suvankar Banerjee,Balaram Ghosh,Tarun Jha et al.
Suvankar Banerjee et al.
Introduction: The processes and course of several fatal illnesses, such as cancer, inflammatory diseases, and neurological disorders are closely correlated with HDAC8. Therefore, novel HDAC8 inhibitors represent effective...